Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: A double-blind randomized controlled trial

Multiple Sclerosis

Volumn 16, Issue 7, 2010, Pages 848-854

  Togha, Mansoureh ^a,e   Karvigh, Sanaz Ahmadi ^a,e   Nabavi, Masoud ^b   Moghadam, Nahid Beladi ^c   Harirchian, Mohammad Hossein ^d,e   Sahraian, Mohammad Ali ^a   Enzevaei, Anahita ^e   Nourian, Alireza ^e   Ghanaati, Hossein ^d,e   Firouznia, Kavous ^d,e   Jannati, Ali ^e   Shekiba, Majid ^d,e  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHED UNIVERSITY   (Iran)

^c Imam Hossein Hospital   (Iran)

^d TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^e TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

interferon beta 1a; relapse; relapsing remitting multiple sclerosis; simvastatin; statin

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; PLACEBO; SIMVASTATIN; BETA INTERFERON; CONTRAST MEDIUM; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOLOGIC FACTOR; IMMUNOLOGICAL ADJUVANT;

ADJUVANT THERAPY; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FATIGUE; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SIDE EFFECT; TREATMENT OUTCOME; DIAGNOSTIC USE; DISABILITY; DRUG COMBINATION; IRAN; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADULT; CONTRAST MEDIA; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; GADOLINIUM; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; IRAN; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SIMVASTATIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77955023091     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458510369147     Document Type: Article

References (25)

1. Neuhaus O., Hartung HP Evaluation of atorvastatin and simvastatin for treatment of multiple sclerosis. Expert Rev Neurother 2007 ; 7: 547-556.
2. Paintlia AS, Paintlia MK, Singh AK, Singh I. Inhibition of rho family functions by lovastatin promotes myelin repair in ameliorating experimental autoimmune encephalomyelitis. Mol Pharmacol 2008 ; 73: 1381-1393.
3. Nath N., Giri S., Prasad R., Singh AK, Singh I. Potential targets of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor for multiple sclerosis therapy. J Immunol 2004 ; 172: 1273-1286.
4. Kieseier BC, Archelos JJ, Hartung HP Different effects of simvastatin and interferon beta on the proteolytic activity of matrix metalloproteinases. Arch Neurol 2004 ; 61: 929-932.
5. Sórensen PS, Frederiksen JL, Lycke J., Sellebjerg F. Does simvastatin antagonize the effect of interferon beta? Interim safety analysis of the ongoing SIMCOMBIN study. Mult Scler 2007 ; 13: S25.
6. Weber MS, Stuve O., Neuhaus O., Hartung HP, Zamvil SS Spotlight on statins. Int MS J 2007 ; 14: 93-97.
7. Dhawan N., Reder A. Statins block interferon signaling in human immune cells: potential loss of the therapeutic effect of IFN-beta in multiple sclerosis. Neurology 2007 ; 68: A364.
8. Aktas O., Waiczies S., Smorodchenko A., et al. Treatment of relapsing paralysis in experimental encephalomyelitis by targeting Th1 cells through atorvastatin. J Exp Med 2003 ; 197: 725-733.
9. Youssef S., Stuve O., Patarroyo JC, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002 ; 420: 78-84.
10. Stanislaus R., Singh AK, Singh I. Lovastatin treatment decreases mononuclear cell infiltration into the CNS of Lewis rats with experimental allergic encephalomyelitis. J Neurosci Res 2001 ; 66: 155-162.
11. Zamvil SS, Steinman L. The T lymphocyte in experimental allergic encephalomyelitis. Annu Rev Immunol 1990 ; 8: 579-621.
12. Paul F., Waiczies S., Wuerfel J., et al. Oral high-dose atorvastatin treatment in relapsing-remitting multiple sclerosis. PLoS One 2008 ; 3: e1928. doi:10.1371.
13. Sellner J., Greeve I., Mattle HP Atorvastatin decreases high-sensitivity C-reactive protein in multiple sclerosis. Mult Scler 2008 ; 14: 981-984.
14. Rudick R., Pace A., Panzara M., et al. Effects of statins on intramuscular interferon beta-1a for relapsing-remitting multiple sclerosis. Mult Scler 2007 ; 13: S57.
15. Neuhas O., Strasser-Fuchs S., Fazekas F., et al. Statins as immunomodulators, comparison with interferon b-1b in MS. Neurology 2002 ; 59: 990-997.
16. McDonald WI, Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guide- lines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 ; 50: 121-127.
17. Gonsette RE Combination therapy for multiple sclerosis. Int MS J 2004 ; 11: 10-21.
18. Vollmer T., Key L., Durkalski V., et al. Oral simvastatin treatment in relapsing-remitting multiple sclerosis. Lancet 2004 ; 363: 1607-1608. (Pubitemid 38625664)
19. Birnbaum G., Altafullah I., Reder AT Combining beta interferon and atorvastatin may increase disease activity in multiple sclerosis. A double-blind placebo controlled trial of atorvastatin in combination with subcutaneous interferon beta 1a in persons with multiple sclerosis. Neurology 2007 ; 68: A206 - A207.
20. McCarey DW, McInnes IB, Madhok R., et al. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet 2004 ; 363: 2015-2021.
21. Araki M., Kondo T., Gumperz JE, Brenner MB, Miyake S., Yamamura T. Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission. Int Immunol 2003 ; 15: 279-288.
22. Sellner J., Greeve I., Findling O., et al. Effect of interferon-beta and atorvastatin on Th1/Th2 cytokines in multiple sclerosis. Neurochem Int 2008 ; 53: 17-21.
23. Carrieri PB, Ladogana P., Di Spigna G., et al. Interleukin-10 and interleukin-12 modulation in patients with relapsing-remitting multiple sclerosis on therapy with interferon-beta 1a: differences in responders and non responders. Immunopharmacol Immunotoxicol 2008 ; 30: 1-9.
24. Stanislaus R., Gilg AG, Singh AK, Singh I. Immunomodulation of experimental autoimmune encephalomyelitis in the Lewis rats by lovastatin. Neurosci Lett 2002 ; 333: 167-170.
25. Orefice G., Quarantelli M., Salvatore P., et al. An open-label, randomized clinical trial of atorvastatin in combination with interferon beta-1a in active MS patients; 12 months results. Mult Scler 2007 ; 13: S56.